SQZ Bio (SQZ) Stock Forecast, Price Target & Predictions
SQZ Stock Forecast
SQZ Bio stock forecast is as follows: an average price target of $400.00 (represents a 786836.85% upside from SQZ’s last price of $0.05) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
SQZ Price Target
The average price target for SQZ Bio (SQZ) is $400.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $400.00 to $400.00. This represents a potential 786836.85% upside from SQZ's last price of $0.05.
SQZ Analyst Ratings
According to 1 Wall Street analysts, SQZ Bio's rating consensus is 'Buy'. The analyst rating breakdown for SQZ stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
SQZ Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 01, 2022 | Chardan Capital | - | - | 119.76% | 786836.85% |
The latest SQZ Bio stock forecast, released on Dec 01, 2022 by Chardan Capital company, set a price target of $400.00, which represents a 119.76% increase from the stock price at the time of the forecast ($182.02), and a 786836.85% increase from SQZ last price ($0.05).
SQZ Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.05 | $0.05 | $0.05 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of SQZ Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to SQZ Bio's last price of $0.05. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 01, 2022 | Chardan Capital | Buy | Buy | Hold |
SQZ Bio's last stock rating was published by Chardan Capital on Dec 01, 2022. The company gave SQZ a "Buy" rating, the same as its previous rate.
SQZ Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SQZ | SQZ Bio | - | - | 90809.09% | Buy |
| PMVP | PMV Pharmaceuticals | - | - | 1018.01% | Buy |
| PCSA | Processa Pharmaceuticals | - | - | 922.73% | Buy |
| ANTX | AN2 Therapeutics | - | - | 611.38% | Buy |
| HOWL | Werewolf Therapeutics | - | - | 574.16% | Buy |
| ANEB | Anebulo Pharmaceuticals | - | - | 300.00% | Buy |
| FENC | Fennec Pharmaceuticals | - | - | 233.69% | Buy |
| IKT | Inhibikase Therapeutics | - | - | 223.38% | Buy |
| NUVB | Nuvation Bio | - | - | 150.00% | Buy |
| KZR | Kezar Life Sciences | - | - | 129.66% | Buy |
| SABS | SAB Biotherapeutics | - | - | 84.69% | Buy |
| MNPR | Monopar Therapeutics | - | - | 49.67% | Buy |
| THRD | Third Harmonic Bio | - | - | 41.05% | Buy |
| LIPO | Lipella Pharmaceuticals | - | - | -17.36% |